Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health
February 13 2024 - 8:01AM
Business Wire
Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare
data and technology solutions announced today the launch of
TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored
initiative aimed at improving cardiovascular health through
increased influenza vaccination education.
Influenza vaccination is associated with a lower risk for
adverse cardiovascular events, with an overall 34% lower risk of
major adverse cardiovascular events and a 45% lower risk among
individuals with recent acute coronary syndrome (ACS).1 As part of
this quality improvement initiative, Veradigm is delivering
ACC-sponsored vaccination education messaging to a subset of
cardiology practices using the Practice Fusion EHR (a Veradigm
Network solution). The messages appear as banner advertisements in
an in-frame window adjacent to the EHR workflow that is separate
and distinguishable from the clinical and practice management
workflow within the EHR.
“Veradigm is proud to be working with the ACC to apply our
real-world data in combination with our messaging capabilities to
improve rates of recommended vaccinations for adults with
cardiovascular disease,” said Stuart Green, Senior Vice President
and General Manager at Veradigm.
“Routine influenza vaccination is an important component of the
evidence-based practice in patients with cardiovascular disease,
but like many other cardiovascular treatments, deep implementation
gaps exist,” said Ankeet S. Bhatt, MD, MBA, ScM, chair of the
TRANSFORM VAX project steering committee. “Together with Veradigm,
the ACC is studying how to reach clinicians in innovative ways to
provide timely, actionable information to close implementation gaps
in influenza vaccination for at-risk cardiovascular patients.”
Powered by Veradigm de-identified real-world data, TRANSFORM VAX
will deliver educational messaging to healthcare providers whose
patient cohorts meet ACC-determined criteria for inclusion. It will
then compare results against a control group of physicians not
receiving TRANSFORM VAX messaging, enabling the ACC to establish
benchmarks from which to measure future quality improvement
success.
“People with heart disease have a much higher risk of serious
complications from the flu, including heart attack, stroke and
heart failure,” said Ami Bhatt, MD, ACC Chief Innovation Officer.
“The ACC is committed to delivering innovative solutions to
transform cardiovascular care and improve heart health by raising
clinician awareness of the benefits of flu vaccination for the most
at-risk patients.”
Veradigm Inc.’s participation in TRANSFORM VAX is supported by
the Centers for Disease Control and Prevention (CDC) of the U.S.
Department of Health and Human Services (HHS) as part of a
financial assistance award to the Council of Medical Specialty
Societies (CMSS), with 100 percent funded by CDC/HHS. The contents
are those of the authors and do not necessarily represent the
official views of nor endorsement, by CDC/HHS or the U.S.
Government.
About Veradigm®
Veradigm is a healthcare technology company that drives value
through its unique combination of platforms, data, expertise,
connectivity, and scale. The Veradigm Network features a dynamic
community of solutions and partners providing advanced insights,
technology, and data-driven solutions for the healthcare provider,
payer, and biopharma markets. For more information about how
Veradigm is fulfilling its mission of Transforming Health,
Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn,
Facebook, Twitter, and YouTube.
References:
- Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD,
Udell JA. Association of Influenza Vaccination With Cardiovascular
Risk: A Meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e228873.
doi: 10.1001/jamanetworkopen.2022.8873. PMID: 35486404; PMCID:
PMC9055450. |
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042
© 2024 Veradigm Inc. and/or its affiliates. All rights
reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213633285/en/
Investors: Jenny Gelinas
312-506-1237 jenny.gelinas@veradigm.com
Media: Concetta Rasiarmos
312-447-2466 concetta.rasiarmos@veradigm.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2023 to Apr 2024